The prognosis of patients with primary CNS lymphoma (PCNSL) who fail high-dose methotrexate (HD-MTX)-based chemotherapy remains poor, particularly in older individuals, and improvements in salvage chemotherapy are needed. The few cytotoxic agents available for this condition demonstrate limited efficacy. 1 Lenalidomide is an immunomodulatory agent, derived from thalidomide, with antiproliferative activities that might act by modifying the tumor microenvironment and activating cytotoxic T and natural killer cells. 2 Its efficacy has been established in multiple myeloma and more recently as a single agent or in combination with rituximab in several types of non-Hodgkin lymphomas. In refractory or relapsed systemic diffuse large B-cell (DLBC) lymphomas, lenalidomide exhibited a 28%-35% response rate with a good safety profile. 3, 4 Interestingly, pomalidomide, a lenalidomide analog, showed activity against CNS lymphoma in murine models and is currently investigated in a phase I study (NCT 01722305). Although little is known about the capacity of lenalidomide to cross the blood-brain barrier, 5 this drug appears to be potentially active in PCNSL. The objective of this retrospective case series was to determine the response rate to a standard dose of lenalidomide.
Level of evidence. This study provides Class IV evidence that for elderly patients with relapsed PCNSL, lenalidomide induced a complete response in 2 of 6 patients.
Methods. Patients with PCNSL treated with lenalidomide at the Pitié-Salpêtrière Hospital, Paris, France, were reviewed retrospectively. The selection criteria were as follows: (1) immunocompetent status; (2) pathologic diagnosis of DLBC PCNSL; (3) recurrent disease after at least 2 prior chemotherapy treatments, including IV HD-MTX-based and cytarabine-based regimens; and (4) oral lenalidomide as monotherapy, at a standard dose of 25 mg/d on days 1-21 of a 28day cycle. Lenalidomide was administered as a compassionate treatment after approval by the French expert center on PCNSL supported by the National Cancer Institute. All patients gave written informed consent. Preventive anticoagulant or antiaggregant therapy was given to prevent thromboembolic events. Clinical and biological evaluations including blood counts, electrolytes, and liver function were performed at each cycle. Cerebral MRI was performed every 4 weeks during the first 3 cycles and every 8 weeks thereafter. Response was assessed according to the IPCG criteria. 6 Results. Six patients (2 men, 4 women) treated between June 2011 and March 2013 met the selection criteria. Their main clinical characteristics and response to treatment are summarized in the table. Median age was 73.5 years (range 64-78) and median Karnofsky Performance Status was 60 (range 40-70). Lenalidomide was administered as third-line therapy for 4 patients, as fourth-line therapy for 1 patient, and as fifth-line therapy for 1 patient. None of them had received prior radiotherapy. Two patients achieved a confirmed complete response (CR). One patient (case 1) achieved CR after the first cycle. This 72-year-old woman, who had failed 2 prior chemotherapy regimens, received a total of 9 monthly cycles without steroids and then decided by herself to stop lenalidomide while tolerance was excellent. She was still in remission 24 months after the start of lenalidomide (figure e-1 on the Neurology ® Web site at Neurology.org); one patient (case 2) achieved dramatic partial response (PR) after 1 cycle and CR after 2 cycles, stopped steroids rapidly, but relapsed at 11 weeks and died rapidly due to lymphoma progressive disease. One patient (case 3) achieved a dramatic partial response after the first cycle but experienced sudden death during the second cycle. Three patients progressed after the first cycle and died 2, 5, and 6 months, respectively, after the start of lenalidomide. Interestingly, one patient (case 5) achieved an ocular response while progressing in the brain. Other than the sudden death of unknown cause, no patients experienced any grade III or grade IV toxicity.
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